Riskpilot← Back to searchSign inGet full accessHerb Pharma Sverige AB
ABActiveOrg 5565643037Storgatan 28Other human health activities n.e.c. · NACE 8699Est. 19981-4 employees
Revenue 2025
SEK 2,4M
-35% vs 2024
EBITDA margin
31.7%
+3287% vs 2024
Equity ratio
63.4%
Financial strength
Net profit 2025
SEK 368K
+22387% vs 2024
| Revenue | SEK 2,4M | -35% |
| EBITDA | SEK 750K | +3287% |
| Net profit | SEK 368K | +22387% |
| Total assets | SEK 2,7M | +5% |
| Equity | SEK 1,7M | +27% |
| Employees | — | — |
Legal name
Herb Pharma Sverige AB
Org number
5565643037
Legal form
Aktiebolag
NACE code
8699 · Other human health activities n.e.c.
Founded
18 december 1998
Share capital
SEK 100 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolagets verksamhet består i att driva medicinsk behandling, utbildning samt framställning och försäljning av kosttillskott inom samma område samt därmed förenlig verksamhet.
Address
Storgatan 28
Phone
+46737882182
Email
anneli.sandstrom@herbpharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 828 | 3 292 | 3 895 | 3 624 | 2 370 |
| Staff expenses | — | — | — | −1 005 | −498 |
| EBITDA | 204 | 100 | 52 | −24 | 750 |
| Depreciation & amort. | −150 | −117 | −171 | −117 | −111 |
| EBIT | 54 | −17 | −119 | −141 | 639 |
| Net financials | −11 | −18 | −20 | −15 | −12 |
| Profit before tax | 22 | −54 | 17 | 13 | 467 |
| Tax | −10 | −0 | −15 | −11 | −99 |
| Net profit | 12 | −54 | 2 | 2 | 368 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 3 297 | 3 668 | 3 016 | 2 577 | 2 717 |
| Equity | 1 404 | 1 350 | 1 352 | 1 354 | 1 722 |
| Long-term debt | 435 | 303 | 171 | 39 | 0 |
| Short-term debt | 881 | 1 419 | 1 054 | 914 | 565 |
| Total debt | 1 316 | 1 722 | 1 225 | 953 | 565 |
EBITDA margin
31.7%
This company
15.8%
Market median
+101% vs market
20212025
Equity ratio
63.4%
This company
38.2%
Market median
+66% vs market
20212025
Return on equity
21.4%
This company
18.4%
Market median
+16% vs market
20212025
Net profit margin
15.5%
This company
8.1%
Market median
+91% vs market
20212025
Asset turnover
0.87×
This company
1.12×
Market median
+22% vs market
20212025
Debt / equity
0.58×
This company
0.62×
Market median
+6% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
KS | Audit | 2022 |
| Former (1) | ||
LM Auditor Substitute | Auditor Substitute | 2020 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Deputy Board Member | 2020 | |
| Deputy Board Member | 2021 | |
| Board of Directors | 2020 | |
| Former (1) | ||
| Deputy Board Member | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Herb Pharma Sverige AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Katrin Susanne Bengtsson | Audit | 0 companies |
| Linda Marie Dunsjö | Auditor Substitute | 0 companies |
| Hanna Sofie Karlsson | Deputy Board Member | 0 companies |
| Andréas Lars-Erik Karlsson | Deputy Board Member | 0 companies |
| Gunbritt Anneli Sandström | Board of Directors | 0 companies |
| Carl Tore Bengtsson | Deputy Board Member | 0 companies |